Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence
Treatment With Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase III Clinical Trial
Lead SponsorAPOGEPHA Arzneimittel GmbH
StatusCompleted No Results Posted
Intervention/Treatmentpropiverine hydrochloride ...
The study was conducted between 2004 and 2006 to prove efficacy and tolerability of the antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic overactive bladder and urinary incontinence.
This clinical trial showed superior efficacy of propiverine over placebo and convincing tolerability for the treatment of children suffering from OAB and urinary incontinence.
propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
placebo corresponding to body weight
Inclusion Criteria: voiding frequency 8 or above per day at least one incontinence episode per day age between 5-10 years body weight between 17 and 45 kg Exclusion Criteria: normal age expected bladder capacity PVR more than 10 ml dysfunctional voiding neurogenic disorders UTI, constipation